MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/mus.26985

Медицинская библиотека · Muscle & nerve · 2020

Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.

Rivner Michael H, Quarles Brandy M, Pan Jin-Xiu, Yu Zheng, Howard James F, Corse Andrea, Dimachkie Mazen M, Jackson Carlayne, Vu Tuan, Small George, Lisak Robert P, Belsh Jerry, Lee Ikjae, Nowak Richard J, Baute Vanessa, Scelsa Stephen, Fernandes J Americo, Simmons Zachary, Swenson Andrea, Barohn Richard, Sanka R Bhavaraju, Gooch Clifton, Ubogu Eroboghene, Caress James, Pasnoor Mamatha, Xu Hongyan, Mei Lin

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

INTRODUCTION

Our aim in this study was to identify the prevalence and clinical characteristics of LRP4/agrin-antibody-positive double-seronegative myasthenia gravis (DNMG).

METHODS

DNMG patients at 16 sites in the United States were tested for LRP4 and agrin antibodies, and the clinical data were collected.

RESULTS

Of 181 DNMG patients, 27 (14.9%) were positive for either low-density lipoprotein receptor-related protein 4 (LRP4) or agrin antibodies. Twenty-three DNMG patients (12.7%) were positive for both antibodies. More antibody-positive patients presented with generalized symptoms (69%) compared with antibody-negative patients (43%) (P ≤ .02). Antibody-positive patients' maximum classification on the Myasthenia Gravis Foundation of America (MGFA) scale was significantly higher than that for antibody-negative patients (P ≤ .005). Seventy percent of antibody-positive patients were classified as MGFA class III, IV, or V compared with 39% of antibody-negative patients. Most LRP4- and agrin-antibody-positive patients (24 of 27, 89%) developed generalized myathenia gravis (MG), but with standard MG treatment 81.5% (22 of 27) improved to MGFA class I or II during a mean follow-up of 11 years.

DISCUSSION: Antibody-positive patients had more severe clinical disease than antibody-negative patients. Most DNMG patients responded to standard therapy regardless of antibody status.

Для цитирования: Rivner Michael H, Quarles Brandy M, Pan Jin-Xiu, Yu Zheng, Howard James F, Corse Andrea, Dimachkie Mazen M, Jackson Carlayne, Vu Tuan, Small George, Lisak Robert P, Belsh Jerry, Lee Ikjae, Nowak Richard J, Baute Vanessa, Scelsa Stephen, Fernandes J Americo, Simmons Zachary, Swenson Andrea, Barohn Richard, Sanka R Bhavaraju, Gooch Clifton, Ubogu Eroboghene, Caress James, Pasnoor Mamatha, Xu Hongyan, Mei Lin. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.. Muscle & nerve. 2020. DOI: 10.1002/mus.26985.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.